Review Finds Antidepressants Ineffective in Children, Teens

This article originally appeared here.
Share this content:
Review Finds Antidepressants Ineffective in Children, Teens
Review Finds Antidepressants Ineffective in Children, Teens

THURSDAY, June 9, 2016 (HealthDay News) -- Treating children and teens suffering from depression with antidepressants may be both ineffective and potentially dangerous, according to a review published online June 8 in The Lancet.

Andrea Cipriani, Ph.D., an associate professor in the department of psychiatry at the University of Oxford in the United Kingdom, and colleagues reviewed 34 studies that included 5,260 children and teens. Most of the trials (65 percent) were financed by drug companies; 90 percent had a risk of being biased in favor of the medication, Cipriani told HealthDay.

Of the 14 antidepressants studied, only fluoxetine was more effective in treating depression than an inactive placebo in children and teens, the researchers found. The antidepressants venlafaxine, imipramine, and duloxetine had the worst side effects, causing more patients to stop taking them than those taking a placebo. And venlafaxine was linked to a higher risk of suicidal thoughts and attempts compared to a placebo and five other antidepressants.

"This study gives us real concern about the usefulness of antidepressants," the author of an accompanying journal editorial, Jon Jureidini, Ph.D., of the Robinson Research Institute at the University of Adelaide in Australia, told HealthDay. "We should shift our practice away from prescribing and toward other treatments, because drugs are being oversold to us." Young children should never be given antidepressants and they should be given sparingly to teens. "I would almost never use them," Jureidini added.

Several study authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »